Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier crushed vs whole tablet bioequivalence study (CRUSADE-2)
NCT03817619Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of grazoprevir in hepatitis C (HCV) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Bioequivalence Area Under the Curve from 0 to 72 hours. Started Mar 2019; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03817619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817619.